Cargando…

Neuroprotection in a Novel Mouse Model of Multiple Sclerosis

Multiple sclerosis is an immune-mediated, demyelinating and neurodegenerative disease that currently lacks any neuroprotective treatments. Innovative neuroprotective trial designs are required to hasten the translational process of drug development. An ideal target to monitor the efficacy of strateg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lidster, Katie, Jackson, Samuel J., Ahmed, Zubair, Munro, Peter, Coffey, Pete, Giovannoni, Gavin, Baker, Mark D., Baker, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817036/ https://www.ncbi.nlm.nih.gov/pubmed/24223903 http://dx.doi.org/10.1371/journal.pone.0079188

Ejemplares similares

Imidazol-1-ylethylindazole Voltage-Gated Sodium Channel Ligands Are Neuroprotective during Optic Neuritis in a Mouse Model of Multiple Sclerosis
por: Browne, Lorcan, et al.
Publicado: (2014)

Correction to Imidazol-1-ylethylindazole Voltage-Gated Sodium Channel Ligands Are Neuroprotective during Optic Neuritis in a Mouse Model of Multiple Sclerosis
por: Browne, Lorcan, et al.
Publicado: (2015)

Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium Channels
por: Pryce, Gareth, et al.
Publicado: (2023)

Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis
por: Hampton, David W, et al.
Publicado: (2013)

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
por: Baker, David, et al.
Publicado: (2017)

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
por: Baker, David, et al.
Publicado: (2020)

Multiple Sclerosis Cerebrospinal Fluid Biomarkers
por: Giovannoni, Gavin
Publicado: (2006)

Resveratrol Neuroprotection in a Chronic Mouse Model of Multiple Sclerosis
por: Fonseca-Kelly, Zoe, et al.
Publicado: (2012)

COVID-19 vaccines and multiple sclerosis disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Multiple Sclerosis and Its Treatment
por: Giovannoni, Gavin, et al.
Publicado: (1999)

Fingolimod modulates microglial activation to augment markers of remyelination
por: Jackson, Samuel J, et al.
Publicado: (2011)

Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB(2) Receptor) in Experimental Autoimmune Encephalomyelitis Models of Multiple Sclerosis
por: Sisay, Sofia, et al.
Publicado: (2013)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Depletion of CD52‐positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune‐tolerance promoting CD8 T‐cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis
por: von Kutzleben, Stephanie, et al.
Publicado: (2017)

Two Years Later: Journals Are Not Yet Enforcing the ARRIVE Guidelines on Reporting Standards for Pre-Clinical Animal Studies
por: Baker, David, et al.
Publicado: (2014)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Predicting Multiple Sclerosis: Challenges and Opportunities
por: Hone, Luke, et al.
Publicado: (2022)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier
por: Yeandle, David, et al.
Publicado: (2018)

The Multiple Sclerosis Care Unit
por: Soelberg Sorensen, Per, et al.
Publicado: (2018)

Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
por: Chun, Jerold, et al.
Publicado: (2020)

Is multiple sclerosis a risk factor for infections?
por: Lechner-Scott, Jeannette, et al.
Publicado: (2020)

Vaccine hesitancy in people with multiple sclerosis
por: Lechner-Scott, Jeannette S, et al.
Publicado: (2022)

Antibodies to neurofilament light as potential biomarkers in multiple sclerosis
por: Puentes, Fabiola, et al.
Publicado: (2021)

Progression in multiple sclerosis is associated with low endogenous NCAM
por: Gnanapavan, Sharmilee, et al.
Publicado: (2013)

The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis
por: Shribman, Samuel, et al.
Publicado: (2017)

The Refinement of Genetic Predictors of Multiple Sclerosis
por: Disanto, Giulio, et al.
Publicado: (2014)

Neuroprotective Effects of 6-Shogaol and Its Metabolite, 6-Paradol, in a Mouse Model of Multiple Sclerosis
por: Sapkota, Arjun, et al.
Publicado: (2019)

Strategies for Neuroprotection in Multiple Sclerosis and the Role of Calcium
por: Enders, Michael, et al.
Publicado: (2020)

Seeking neuroprotection in multiple sclerosis: an ongoing challenge
por: Antel, Jack P., et al.
Publicado: (2023)

Meta-Analysis of the Relationship between Multiple Sclerosis and Migraine
por: Pakpoor, Julia, et al.
Publicado: (2012)

Visibility and representation of women in multiple sclerosis research
por: Thomson, Alison, et al.
Publicado: (2019)

Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis
por: Licht-Mayer, Simon, et al.
Publicado: (2020)

The Potential for EBV Vaccines to Prevent Multiple Sclerosis
por: Maple, Peter A., et al.
Publicado: (2022)

Optimizing treatment success in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome
por: Ammar, Reham A., et al.
Publicado: (2022)

Smoking and Multiple Sclerosis: An Updated Meta-Analysis
por: Handel, Adam E., et al.
Publicado: (2011)

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2017)

MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iqka1klbuv3odlucafuedbgocd